BRPI0918724A8 - Composto inibidor de protease de serina para hepatite c macrocíclica - Google Patents
Composto inibidor de protease de serina para hepatite c macrocíclicaInfo
- Publication number
- BRPI0918724A8 BRPI0918724A8 BRPI0918724A BRPI0918724A BRPI0918724A8 BR PI0918724 A8 BRPI0918724 A8 BR PI0918724A8 BR PI0918724 A BRPI0918724 A BR PI0918724A BR PI0918724 A BRPI0918724 A BR PI0918724A BR PI0918724 A8 BRPI0918724 A8 BR PI0918724A8
- Authority
- BR
- Brazil
- Prior art keywords
- serine protease
- inhibitory compound
- protease inhibitory
- macrocyclic
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19172508P | 2008-09-11 | 2008-09-11 | |
US61/191.725 | 2008-09-11 | ||
US20968909P | 2009-03-10 | 2009-03-10 | |
US61/209.689 | 2009-03-10 | ||
PCT/US2009/005082 WO2010030359A2 (en) | 2008-09-11 | 2009-09-10 | Macrocyclic hepatitis c serine protease inhibitors |
Publications (4)
Publication Number | Publication Date |
---|---|
BRPI0918724A2 BRPI0918724A2 (pt) | 2013-06-18 |
BRPI0918724A8 true BRPI0918724A8 (pt) | 2017-10-03 |
BRPI0918724B1 BRPI0918724B1 (pt) | 2019-12-03 |
BRPI0918724B8 BRPI0918724B8 (pt) | 2021-05-25 |
Family
ID=42005677
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122012005261A BR122012005261A8 (pt) | 2008-09-11 | 2009-09-10 | Inibidores de protease de serina para hepatite c macrocíclica no tratamento de infecção por hcv |
BRPI0918724A BRPI0918724B8 (pt) | 2008-09-11 | 2009-09-10 | composto inibidor de protease de serina para hepatite c macrocíclica |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR122012005261A BR122012005261A8 (pt) | 2008-09-11 | 2009-09-10 | Inibidores de protease de serina para hepatite c macrocíclica no tratamento de infecção por hcv |
Country Status (41)
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY32099A (es) * | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
US8937150B2 (en) * | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
MX2012003500A (es) * | 2009-09-28 | 2012-08-01 | Intermune Inc | Nuevos inhibidores macrocíclicos de la replicación de virus de la hepatitis c. |
EA201201031A1 (ru) | 2010-01-25 | 2013-02-28 | Энанта Фармасьютиклз, Инк. | Ингибиторы вируса гепатита с |
US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
CN104771364B (zh) * | 2010-03-10 | 2018-05-25 | 艾伯维巴哈马有限公司 | 固体组合物 |
JP2014502620A (ja) * | 2010-12-30 | 2014-02-03 | エナンタ ファーマシューティカルズ インコーポレイテッド | 大環状c型肝炎セリンプロテアーゼ阻害剤 |
CN103380132B (zh) * | 2010-12-30 | 2016-08-31 | 益安药业 | 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂 |
US9044480B1 (en) | 2011-03-03 | 2015-06-02 | Abbvie Inc. | Compositions and methods for treating HCV |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
CA2847355A1 (en) | 2011-09-16 | 2013-03-21 | Abbvie Inc. | Methods for treating hcv |
CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333) |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
UY34402A (es) * | 2011-10-21 | 2013-05-31 | Abbvie Inc | Métodos para el tratamiento de hcv |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
AU2015200715A1 (en) * | 2011-10-21 | 2015-03-05 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US9346785B2 (en) * | 2012-01-11 | 2016-05-24 | Abbvie Inc. | Process for making HCV protease inhibitors |
CN104379145A (zh) | 2012-06-27 | 2015-02-25 | 艾伯维公司 | Abt-450和利托那韦和例如abt-072和/或abt-333用于在治疗hcv中使用的联合治疗 |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
CN104603138A (zh) * | 2012-07-12 | 2015-05-06 | 艾伯维公司 | Hcv抑制剂的晶形 |
TW201408669A (zh) | 2012-08-08 | 2014-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
LT2909205T (lt) | 2012-10-19 | 2016-12-27 | Bristol-Myers Squibb Company | 9-metilpakeistieji heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4)diazaciklopentadecinilkarbamato dariniai, kaip nestruktūrinės 3 (ns3) proteazės inhibitoriai, skirti hepatito c viruso infekcijų gydymui |
WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
CN104884459A (zh) * | 2013-01-10 | 2015-09-02 | 百时美施贵宝公司 | 用于治疗丙型肝炎的大环苯并呋喃和氮杂苯并呋喃化合物 |
CN105164148A (zh) | 2013-03-07 | 2015-12-16 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
EA029088B1 (ru) | 2013-03-15 | 2018-02-28 | Джилид Сайэнс, Инк. | Макроциклические и бициклические ингибиторы вируса гепатита c |
MX2015017953A (es) | 2013-07-02 | 2016-10-28 | Abbvie Inc | Metodos para tratar el virus de hepatitis c. |
WO2015038596A1 (en) | 2013-09-11 | 2015-03-19 | Emory University | Nucleotide and nucleoside compositions and uses related thereto |
US20150175612A1 (en) * | 2013-12-04 | 2015-06-25 | Abbvie Inc. | Crystal forms |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
WO2015116594A1 (en) | 2014-01-28 | 2015-08-06 | Abbvie Inc. | Dose adjustment in combination therapy of hepatitis c |
US20160074462A1 (en) | 2014-09-11 | 2016-03-17 | Abbvie Inc. | Method of Treating HCV |
US10059969B1 (en) | 2014-10-03 | 2018-08-28 | Abbvie Inc. | Process for the preparation of (S)-2-amino-non-8-enoic acid |
US10113152B1 (en) | 2014-10-03 | 2018-10-30 | Abbvie Inc. | Variant polypeptides capable of aminating aliphatic alpha keto acids |
KR20170083108A (ko) * | 2014-11-10 | 2017-07-17 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | C형 간염에 대한 장기 작용 약학적 조성물 |
WO2016134058A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Combinations useful to treat hepatitis c virus |
US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
AU2016297024B2 (en) | 2015-07-22 | 2021-03-04 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as RSV inhibitors |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
AU2018215337A1 (en) | 2017-02-01 | 2019-08-22 | Abbvie Inc. | Enzymatic processes for the preparation of (±)-2-(difluoromethyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid and(±)-2-(vinyl)-1-(alkoxycarbonyl)-cyclopropanecarboxylic acid |
CN107383021A (zh) * | 2017-08-01 | 2017-11-24 | 安徽拜善晟制药有限公司 | 一种原料药帕利普韦的制备方法 |
WO2020190935A1 (en) | 2019-03-18 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as rsv inhibitors |
US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
UY39032A (es) * | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
CN111378007B (zh) * | 2020-05-08 | 2022-04-12 | 杭州濡湜生物科技有限公司 | 一种采用第二代Hoveyda-Grubbs催化剂制备帕利普韦的方法 |
US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
US11922331B2 (en) | 2020-08-26 | 2024-03-05 | Northrop Grumman Systems Corporation | Machine-learning-based predictive ice detection |
WO2022086840A1 (en) | 2020-10-19 | 2022-04-28 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
BR112023016970A2 (pt) | 2021-02-26 | 2023-10-10 | Enanta Pharm Inc | Compostos heterocíclicos antivirais |
Family Cites Families (252)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5831002A (en) | 1992-05-20 | 1998-11-03 | Basf Aktiengesellschaft | Antitumor peptides |
US5861297A (en) | 1996-09-27 | 1999-01-19 | Merck & Co., Inc. | Detergent-free hepatitis C protease |
CA2294049A1 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor peptides |
US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
US20040058982A1 (en) | 1999-02-17 | 2004-03-25 | Bioavailability System, Llc | Pharmaceutical compositions |
AU3376699A (en) | 1998-03-31 | 1999-10-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
US7122627B2 (en) | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
JP2003526634A (ja) | 1999-12-03 | 2003-09-09 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | C型肝炎ウイルスNS3プロテアーゼのα−ケトアミド阻害剤 |
WO2001064678A2 (en) * | 2000-02-29 | 2001-09-07 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
BR0115447A (pt) * | 2000-11-20 | 2005-10-18 | Bristol Myers Squibb Co | Inibidores de tripeptìdeo de hepatite c |
US6653295B2 (en) | 2000-12-13 | 2003-11-25 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus NS3 protease |
WO2002048157A2 (en) * | 2000-12-13 | 2002-06-20 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors |
FR2821272B1 (fr) | 2001-02-23 | 2004-12-17 | Synt Em | Composes constitues d'une molecule analgesique liee a un vecteur capable de vectoriser ladite molecule a travers la barriere hematoencephalique et compositions pharmaceutiques les contenant |
WO2003025563A1 (en) | 2001-09-16 | 2003-03-27 | Chemometec A/S | Method and a system for detecting and optionally isolating a rare event particle |
AU2002337765A1 (en) | 2001-09-26 | 2003-04-07 | Bristol-Myers Squibb Company | Compounds useful for treating hepatitus c virus |
US6867185B2 (en) * | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US6828301B2 (en) | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
US6869964B2 (en) * | 2002-05-20 | 2005-03-22 | Bristol-Myers Squibb Company | Heterocyclicsulfonamide hepatitis C virus inhibitors |
EP1505945B1 (en) * | 2002-05-20 | 2008-11-05 | Bristol-Myers Squibb Company | Substituted cycloalkyl p1' hepatitis c virus inhibitors |
US20060199773A1 (en) | 2002-05-20 | 2006-09-07 | Sausker Justin B | Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
EP1506172B1 (en) * | 2002-05-20 | 2011-03-30 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US20030232386A1 (en) | 2002-06-17 | 2003-12-18 | Shah Dinesh O. | Assay conjugate and uses thereof |
WO2004002405A2 (en) * | 2002-06-26 | 2004-01-08 | Bristol-Myers Squibb Company | Amino-bicyclic pyrazinones and pyridinones |
WO2004014852A2 (en) * | 2002-08-12 | 2004-02-19 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
US20040138109A1 (en) | 2002-09-30 | 2004-07-15 | Boehringer Ingelheim Pharmaceuticals, Inc. | Potent inhibitor of HCV serine protease |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US20050159345A1 (en) | 2002-10-29 | 2005-07-21 | Boehringer Ingelheim International Gmbh | Composition for the treatment of infection by Flaviviridae viruses |
US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US20040180815A1 (en) | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
WO2004072243A2 (en) * | 2003-02-07 | 2004-08-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis c serine protease inhibitors |
JP4550824B2 (ja) | 2003-03-05 | 2010-09-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎抑制化合物 |
UY28240A1 (es) | 2003-03-27 | 2004-11-08 | Boehringer Ingelheim Pharma | Fases cristalinas de un potente inhibidor de la hcv |
RS20050741A (en) * | 2003-04-02 | 2007-06-04 | Boehringer Ingelheim International Gmbh., | Pharmaceutical compositions for hepatitis c viral protease inhibitors |
JP4231524B2 (ja) | 2003-04-10 | 2009-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 大環状化合物の製造方法 |
EP1615949A1 (en) | 2003-04-10 | 2006-01-18 | Boehringer Ingelheim International GmbH | Process for the preparation of macrocyclic compounds by ruthenium complex catalysed metathesis reaction |
US7173004B2 (en) | 2003-04-16 | 2007-02-06 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus |
EP1615613B1 (en) * | 2003-04-18 | 2009-11-04 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
KR101115294B1 (ko) | 2003-05-21 | 2012-04-12 | 베링거 인겔하임 인터내셔날 게엠베하 | C형 간염 억제제 화합물 |
US7273851B2 (en) | 2003-06-05 | 2007-09-25 | Enanta Pharmaceuticals, Inc. | Tri-peptide hepatitis C serine protease inhibitors |
US7112601B2 (en) | 2003-09-11 | 2006-09-26 | Bristol-Myers Squibb Company | Cycloalkyl heterocycles for treating hepatitis C virus |
EA200600498A1 (ru) * | 2003-09-22 | 2006-10-27 | Бёрингер Ингельхайм Интернациональ Гмбх | Макроциклические пептиды, проявляющие противовирусную активность в отношении вируса гепатита с |
US7592419B2 (en) | 2003-09-26 | 2009-09-22 | Schering Corporation | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
AP2287A (en) | 2003-10-14 | 2011-10-31 | Intermune Inc | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication. |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7309708B2 (en) | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2546290A1 (en) | 2003-11-20 | 2005-06-09 | Schering Corporation | Depeptidized inhibitors of hepatitis c virus ns3 protease |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
FR2863268B1 (fr) | 2003-12-09 | 2006-02-24 | Sod Conseils Rech Applic | Nouveaux derives du 2-hydroxytetrahydrofuranne et leur application a titre de medicaments |
CN100509784C (zh) | 2003-12-11 | 2009-07-08 | 先灵公司 | 丙型肝炎病毒ns3/ns4a丝氨酸蛋白酶的抑制剂 |
ES2358333T3 (es) | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos con acción contra el virus de la hepatitis c. |
DE602005011402D1 (de) | 2004-01-28 | 2009-01-15 | Boehringer Ingelheim Pharma | Übergangsmetallnebenprodukte enthaltenden reaktionslösungen |
CA2552319C (en) | 2004-01-30 | 2012-08-21 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
BRPI0508867A (pt) | 2004-03-15 | 2007-09-04 | Boehringer Ingelheim Int | processo para a preparação de compostos macrocìclicos |
AU2005228894B9 (en) | 2004-03-30 | 2011-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
CA2568008C (en) | 2004-05-25 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Process for preparing acyclic hcv protease inhibitors |
US7705146B2 (en) | 2004-06-28 | 2010-04-27 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor peptide analogs |
DE102004033312A1 (de) * | 2004-07-08 | 2006-01-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Kontinuierliches Metatheseverfahren mit Ruthenium-Katalysatoren |
ATE516293T1 (de) * | 2004-07-16 | 2011-07-15 | Gilead Sciences Inc | Antivirale verbindungen |
UY29016A1 (es) * | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
JP4914355B2 (ja) * | 2004-07-20 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎インヒビターペプチド類似体 |
US7348425B2 (en) * | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
EP1794178A1 (en) | 2004-09-17 | 2007-06-13 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic hcv protease inhibitors |
EP1794179A1 (en) * | 2004-09-17 | 2007-06-13 | Boehringer Ingelheim International Gmbh | Ring-closing metathesis process in supercritical fluid |
US20060068007A1 (en) * | 2004-09-24 | 2006-03-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | Class of surfactant-like materials |
WO2007001406A2 (en) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Aryl-containing macrocyclic compounds |
WO2006039841A1 (en) * | 2004-10-14 | 2006-04-20 | Wuxi Pharma Tech Co., Ltd. | A NOVEL PROCESS FOR THE PREPARATION OF NONRACEMIC LONG CHAIN α-AMINO ACIDS DERIVATIVES |
MX2007004783A (es) | 2004-10-21 | 2007-05-11 | Pfizer | Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan. |
US7323447B2 (en) * | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7608614B2 (en) | 2005-03-08 | 2009-10-27 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
US20080188494A1 (en) | 2005-04-25 | 2008-08-07 | Basf Aktiengesellschaft | Use Of 5-Alkyl-6-Phenylalkyl-7-Aminoazolopyrimidines, Novel Azolopyrimidines, Processes For Their Preparation And Compositions Comprising Them |
EP1879607B1 (en) | 2005-05-02 | 2014-11-12 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
AU2006254538A1 (en) | 2005-05-25 | 2006-12-07 | 2Curex Aps | Compounds modifying apoptosis |
WO2006130553A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors |
WO2006130627A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods for treating hepatitis c |
EP1898941A2 (en) | 2005-06-02 | 2008-03-19 | Schering Corporation | Controlled-release formulation useful for treating disorders associated with hepatitis c virus |
US20060275366A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Controlled-release formulation |
WO2006130666A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Medicaments and methods combining a hcv protease inhibitor and an akr competitor |
CA2611155A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Pharmaceutical formulations and methods of treatment using the same |
US20070237818A1 (en) | 2005-06-02 | 2007-10-11 | Malcolm Bruce A | Controlled-release formulation of HCV protease inhibitor and methods using the same |
WO2006130554A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis c virus |
US20060287248A1 (en) | 2005-06-02 | 2006-12-21 | Schering Corporation | Asymmetric dosing methods |
WO2006130686A2 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors in combination with food |
US20060281689A1 (en) | 2005-06-02 | 2006-12-14 | Schering Corporation | Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period |
US20070021351A1 (en) | 2005-06-02 | 2007-01-25 | Schering Corporation | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor |
US20060276406A1 (en) | 2005-06-02 | 2006-12-07 | Schering Corporation | Methods of treating hepatitis C virus |
US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
CN102643175B (zh) | 2005-07-04 | 2014-12-10 | 赞南科技(上海)有限公司 | 钌络合物配体、钌络合物、固载钌络合物催化剂及其制备方法和用途 |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TW200738742A (en) * | 2005-07-14 | 2007-10-16 | Gilead Sciences Inc | Antiviral compounds |
TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
WO2007009227A1 (en) | 2005-07-20 | 2007-01-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
EP2305695A3 (en) | 2005-07-25 | 2011-07-27 | Intermune, Inc. | Macrocyclic inhibitors of Hepatitis C virus replication |
ES2373685T3 (es) | 2005-07-29 | 2012-02-07 | Tibotec Pharmaceuticals | Inhibidores macrocíclicos del virus de la hepatitis c. |
EP1913015B1 (en) | 2005-07-29 | 2013-12-11 | Janssen R&D Ireland | Macrocyclic inhibitors of hepatitis c virus |
MY139988A (en) | 2005-07-29 | 2009-11-30 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis c virus |
JO2768B1 (en) | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
PE20070343A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Inhibidores macrociclicos del virus de la hepatitis c |
AU2006274862B2 (en) | 2005-07-29 | 2012-03-22 | Medivir Ab | Macrocyclic inhibitors of hepatitis C virus |
JP4705984B2 (ja) | 2005-08-01 | 2011-06-22 | メルク・シャープ・エンド・ドーム・コーポレイション | Hcvns3プロテアーゼ阻害剤としての大環状ペプチド |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
ATE510846T1 (de) | 2005-09-09 | 2011-06-15 | Boehringer Ingelheim Int | Cyclisierendes metatheseverfahren zur herstellung von makrocyclischen peptiden |
US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7473688B2 (en) * | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
US7723336B2 (en) * | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
CN101415705B (zh) | 2005-10-11 | 2011-10-26 | 因特蒙公司 | 抑制丙型肝炎病毒复制的化合物和方法 |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
JP2009530382A (ja) | 2006-03-23 | 2009-08-27 | シェーリング コーポレイション | Hcvプロテアーゼインヒビターとcyp3a4インヒビターとの組み合わせ、および関連する処置方法 |
WO2007130592A2 (en) * | 2006-05-04 | 2007-11-15 | Crawford Ted C | Head cap for a wrench head, wrench and method utilizing the same |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US7521443B2 (en) | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7456166B2 (en) | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
US7521441B2 (en) | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
WO2007140200A2 (en) | 2006-05-25 | 2007-12-06 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
US20070281884A1 (en) | 2006-06-06 | 2007-12-06 | Ying Sun | Macrocyclic oximyl hepatitis C protease inhibitors |
US9526769B2 (en) | 2006-06-06 | 2016-12-27 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
US8268776B2 (en) | 2006-06-06 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Macrocylic oximyl hepatitis C protease inhibitors |
US7452876B2 (en) | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
PE20080992A1 (es) | 2006-06-26 | 2008-08-06 | Enanta Pharm Inc | Quinoxalinil macrociclicos inhibidores de serina proteasa del virus de la hepatitis c |
WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
EP2374812B1 (en) | 2006-07-13 | 2015-04-15 | Achillion Pharmaceuticals, Inc. | 4-amino-4-oxobutanoyl Peptides as Inhibitors of Viral Replication |
WO2008019289A2 (en) * | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
US20090035271A1 (en) * | 2007-08-01 | 2009-02-05 | Ying Sun | Tetrazolyl macrocyclic hepatitis c serine protease inhibitors |
WO2008019303A2 (en) | 2006-08-04 | 2008-02-14 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors |
US7635683B2 (en) * | 2006-08-04 | 2009-12-22 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl tripeptide hepatitis C virus inhibitors |
WO2008021960A2 (en) | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Triazolyl macrocyclic hepatitis c serine protease inhibitors |
US7605126B2 (en) | 2006-08-11 | 2009-10-20 | Enanta Pharmaceuticals, Inc. | Acylaminoheteroaryl hepatitis C virus protease inhibitors |
WO2008022006A2 (en) | 2006-08-11 | 2008-02-21 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis c virus protease inhibitors |
US20080038225A1 (en) * | 2006-08-11 | 2008-02-14 | Ying Sun | Triazolyl acyclic hepatitis c serine protease inhibitors |
US7687459B2 (en) * | 2006-08-11 | 2010-03-30 | Enanta Pharmaceuticals, Inc. | Arylalkoxyl hepatitis C virus protease inhibitors |
US7582605B2 (en) * | 2006-08-11 | 2009-09-01 | Enanta Pharmaceuticals, Inc. | Phosphorus-containing hepatitis C serine protease inhibitors |
CA2664156A1 (en) | 2006-09-27 | 2008-04-03 | Coley Pharmaceutical Group, Inc. | Compositions of tlr ligands and antivirals |
AU2007323035B2 (en) | 2006-10-03 | 2011-11-24 | Cadila Healthcare Limited | Antidiabetic compounds |
US20120220520A1 (en) | 2006-10-17 | 2012-08-30 | Van T Klooster Gerben Albert Eleutherius | Bioavailable combinations for hcv treatment |
US8138164B2 (en) | 2006-10-24 | 2012-03-20 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
AU2007309488B2 (en) | 2006-10-24 | 2012-10-11 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
KR101615500B1 (ko) | 2006-10-27 | 2016-04-27 | 머크 샤프 앤드 돔 코포레이션 | Hcv ns3 프로테아제 억제제 |
CN101568346B (zh) | 2006-10-27 | 2015-11-25 | 默沙东公司 | Hcv ns3蛋白酶抑制剂 |
US20080107623A1 (en) | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
US20080107625A1 (en) * | 2006-11-01 | 2008-05-08 | Bristol-Myers Squibb Company | Inhibitors of Hepatitis C Virus |
US8343477B2 (en) * | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
TW200827364A (en) * | 2006-11-02 | 2008-07-01 | Taigen Biotechnology Co Ltd | HCV protease inhibitors |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI406660B (zh) * | 2006-11-17 | 2013-09-01 | Tibotec Pharm Ltd | C型肝炎病毒之巨環抑制劑 |
WO2008070733A2 (en) | 2006-12-06 | 2008-06-12 | Phenomix Corporation | Macrocyclic hepatitis c serine protease inhibitors and uses therefor |
CA2679563A1 (en) | 2007-01-08 | 2008-07-17 | Phenomix Corporation | Macrocyclic hepatitis c protease inhibitors |
US7541351B2 (en) | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US20080207528A1 (en) | 2007-02-01 | 2008-08-28 | Syaulan Yang | Hcv protease inhibitors |
NZ577568A (en) | 2007-02-01 | 2012-02-24 | Tibotec Pharm Ltd | Polymorphic forms of N-[17-[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13 -diazatricyclo[13.3.0.0^4,6]octadec-7-ene-4-carbonyl](cyclopropyl)sulfonamide |
AU2008212758B2 (en) * | 2007-02-08 | 2014-01-30 | Medivir Ab | Pyrimidine substituted macrocyclic HCV inhibitors |
CA2677015C (en) | 2007-02-08 | 2015-05-26 | Tibotec Pharmaceuticals Ltd. | Hcv inhibiting macrocyclic phenylcarbamates |
EP2125870A4 (en) | 2007-02-16 | 2011-04-06 | Boehringer Ingelheim Int | INHIBITORS OF NS3 PROTEASE OF HEPATITIS C |
CN101663284A (zh) | 2007-02-20 | 2010-03-03 | 诺瓦提斯公司 | 作为hcv ns3蛋白酶抑制剂的大环化合物 |
US8435984B2 (en) | 2007-02-26 | 2013-05-07 | Achillion Pharmaceuticals, Inc. | Tertiary amine substituted peptides useful as inhibitors of HCV replication |
WO2008114006A1 (en) | 2007-03-19 | 2008-09-25 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators |
WO2008124384A2 (en) | 2007-04-03 | 2008-10-16 | Aegerion Pharmaceuticals, Inc. | Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c |
MX2009011370A (es) | 2007-04-24 | 2009-11-05 | Hoffmann La Roche | Proceso para el intermediario del inhibidor proteasa de hcv. |
US20080267917A1 (en) | 2007-04-26 | 2008-10-30 | Deqiang Niu | N-functionalized amides as hepatitis c serine protease inhibitors |
US8377872B2 (en) | 2007-04-26 | 2013-02-19 | Enanta Pharmaceuticals, Inc. | Cyclic P3 tripeptide hepatitis C serine protease inhibitors |
US20080279821A1 (en) | 2007-04-26 | 2008-11-13 | Deqiang Niu | Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors |
US7906513B2 (en) | 2007-04-26 | 2011-03-15 | Enanta Pharmaceuticals, Inc. | Hydrazide-containing hepatitis C serine protease inhibitors |
US20090155209A1 (en) | 2007-05-03 | 2009-06-18 | Blatt Lawrence M | Novel macrocyclic inhibitors of hepatitis c virus replication |
EP2185524A1 (en) | 2007-05-10 | 2010-05-19 | Intermune, Inc. | Novel peptide inhibitors of hepatitis c virus replication |
US20090005387A1 (en) * | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
CN101801925A (zh) | 2007-06-29 | 2010-08-11 | 吉里德科学公司 | 抗病毒组合物 |
CA2691442C (en) | 2007-06-29 | 2014-01-21 | Gilead Sciences, Inc. | Antiviral compounds |
WO2009005690A2 (en) * | 2007-06-29 | 2009-01-08 | Gilead Sciences, Inc. | Antiviral compounds |
CA2699891C (en) * | 2007-07-19 | 2013-10-22 | Nigel Liverton | Macrocyclic compounds as antiviral agents |
WO2009014730A1 (en) | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
WO2009053828A2 (en) | 2007-10-22 | 2009-04-30 | Enanta Pharmaceuticals, Inc. | P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors |
US20090111757A1 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
US8426360B2 (en) | 2007-11-13 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Carbocyclic oxime hepatitis C virus serine protease inhibitors |
SI2209789T1 (sl) | 2007-11-20 | 2012-06-29 | Bristol Myers Squibb Co | Ciklopropil zliti indolobenzazepin hcv ns5b inhibitorji |
US8263549B2 (en) | 2007-11-29 | 2012-09-11 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors |
US8030307B2 (en) | 2007-11-29 | 2011-10-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease |
JP2011506329A (ja) * | 2007-12-05 | 2011-03-03 | エナンタ ファーマシューティカルズ インコーポレイテッド | キノキサリニル誘導体 |
WO2009073713A1 (en) | 2007-12-05 | 2009-06-11 | Enanta Pharmaceuticals, Inc. | Oximyl macrocyclic derivatives |
EP2224920A4 (en) | 2007-12-06 | 2012-05-09 | Enanta Pharm Inc | PROCESS FOR THE PREPARATION OF MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS |
CN101903391B (zh) | 2007-12-21 | 2013-04-03 | 弗·哈夫曼-拉罗切有限公司 | 大环化合物的制备方法 |
US8309685B2 (en) * | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
MX2010006736A (es) | 2007-12-21 | 2010-10-15 | Avila Therapeutics Inc | Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos. |
US8293705B2 (en) * | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
MX2010006738A (es) | 2007-12-21 | 2010-10-15 | Avila Therapeutics Inc | Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos. |
CN101977915B (zh) | 2008-02-04 | 2014-08-13 | 埃迪尼克斯医药公司 | 大环丝氨酸蛋白酶抑制剂 |
US20100081713A1 (en) * | 2008-03-19 | 2010-04-01 | CombinatoRx, (Singapore) Pte. Ltd. | Compositions and methods for treating viral infections |
MX2010011306A (es) * | 2008-04-15 | 2010-11-09 | Intermune Inc | Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c. |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2285822A1 (en) | 2008-05-09 | 2011-02-23 | Boehringer Ingelheim International GmbH | A method for preparing macrocycles |
US20090285773A1 (en) | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US20090285774A1 (en) | 2008-05-15 | 2009-11-19 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
CN101580535B (zh) | 2008-05-16 | 2012-10-03 | 太景生物科技股份有限公司 | 丙型肝炎病毒蛋白酶抑制剂 |
JP5529120B2 (ja) | 2008-05-29 | 2014-06-25 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎ウイルス阻害剤 |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2009149377A1 (en) | 2008-06-05 | 2009-12-10 | Zymogenetics, Llc | Use of pegylated type iii interferons for the treatment of hepatitis c |
AR072428A1 (es) | 2008-07-01 | 2010-08-25 | Medivir Ab | Derivados de pirimidin nucleotidos inhibidores de polimerasas del virus de la hepatitis c (vhc), composiciones farmaceuticas que los contienen y metodo para prepararlos. |
ES2461841T3 (es) * | 2008-08-07 | 2014-05-21 | F. Hoffmann-La Roche Ag | Proceso para la preparación de un macrociclo |
CA2734744A1 (en) | 2008-08-20 | 2010-02-25 | Michael Eissenstat | Hcv protease inhibitors |
RU2014150660A (ru) | 2008-09-05 | 2015-07-20 | Селджен Авиломикс Рисерч, Инк. | Алгоритм разработки необратимо действующих ингибиторов |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
WO2010033466A1 (en) | 2008-09-16 | 2010-03-25 | Phenomix Corporation | Macrocyclic inhibitors of hepatitis c protease |
NZ602163A (en) * | 2008-09-16 | 2013-06-28 | Boehringer Ingelheim Int | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent hepatitis c viral inhibitor |
BRPI0918653A2 (pt) | 2008-09-17 | 2015-12-01 | Boehringer Ingelheim Int | combinação de inibidor de ns3 protese de hcv com interferon e ribavirina. |
US8603737B2 (en) * | 2008-09-19 | 2013-12-10 | Celgene Avilomics Research, Inc. | Methods for identifying HCV protease inhibitors |
JP2012502925A (ja) | 2008-09-23 | 2012-02-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎阻害化合物 |
US8044087B2 (en) * | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) * | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20100080770A1 (en) * | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
EP2346329B1 (en) | 2008-10-09 | 2013-08-21 | Anadys Pharmaceuticals, Inc. | A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds |
WO2010048468A1 (en) | 2008-10-23 | 2010-04-29 | Concert Pharmaceuticals, Inc. | Deuterated macrocyclic inhibitors of viral ns3 protease |
US8296141B2 (en) * | 2008-11-19 | 2012-10-23 | At&T Intellectual Property I, L.P. | System and method for discriminative pronunciation modeling for voice search |
US8445430B2 (en) * | 2008-11-20 | 2013-05-21 | Achillion Pharmaceuticals, Inc. | Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus |
DK2358355T3 (da) | 2008-11-21 | 2013-12-16 | Boehringer Ingelheim Int | Farmaceutisk sammensætning af en potent HCV-inhibitor til oral indgivelse |
US20100272674A1 (en) | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MX2011006631A (es) | 2008-12-19 | 2011-09-06 | Gilead Sciences Inc | Inhibidores de proteasa ns3 del virus hcv. |
EP2393493A4 (en) | 2009-01-30 | 2013-07-17 | Glaxosmithkline Llc | LINKS |
US8642544B2 (en) | 2009-04-01 | 2014-02-04 | Amylin Pharmaceuticals, Llc | N-terminus conformationally constrained GLP-1 receptor agonist compounds |
WO2010118078A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
WO2010128521A2 (en) | 2009-04-24 | 2010-11-11 | Cadila Healthcare Limited | Short-chain peptides as parathyroid hormone (pth) receptor agonist |
WO2010135520A1 (en) | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
EP2432318A4 (en) | 2009-05-22 | 2012-11-21 | Sequoia Pharmaceuticals Inc | NS3 PROTEASE INHIBITORS OF BIPACROCYCLIC HEPATITIS C VIRUS |
US8232246B2 (en) | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
WO2011009961A1 (en) * | 2009-07-24 | 2011-01-27 | Virologik Gmbh | Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis |
JP2013501068A (ja) | 2009-08-05 | 2013-01-10 | アイディニックス ファーマシューティカルズ インコーポレイテッド | 大環状セリンプロテアーゼ阻害剤 |
AU2009352688B2 (en) * | 2009-09-15 | 2014-04-17 | Taigen Biotechnology Co., Ltd. | HCV protease inhibitors |
WO2011063501A1 (en) | 2009-11-24 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
JP2013511562A (ja) | 2009-11-24 | 2013-04-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎阻害化合物 |
US20110178107A1 (en) | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
-
2009
- 2009-09-09 UY UY0001032099A patent/UY32099A/es active IP Right Grant
- 2009-09-10 TW TW098130581A patent/TWI429449B/zh active
- 2009-09-10 SI SI200931860T patent/SI2805726T1/sl unknown
- 2009-09-10 TW TW101110209A patent/TWI450723B/zh not_active IP Right Cessation
- 2009-09-10 DK DK12160849.1T patent/DK2468286T3/da active
- 2009-09-10 PT PT121610471T patent/PT2468287E/pt unknown
- 2009-09-10 AR ARP090103469A patent/AR073568A1/es active IP Right Grant
- 2009-09-10 ES ES09813360.6T patent/ES2459390T3/es active Active
- 2009-09-10 NZ NZ605550A patent/NZ605550A/en not_active IP Right Cessation
- 2009-09-10 PL PL14181565T patent/PL2805726T3/pl unknown
- 2009-09-10 PT PT121607790T patent/PT2468285E/pt unknown
- 2009-09-10 ES ES12160779.0T patent/ES2525922T3/es active Active
- 2009-09-10 SI SI200930970T patent/SI2468287T1/sl unknown
- 2009-09-10 PE PE2011000597A patent/PE20110704A1/es active IP Right Grant
- 2009-09-10 TR TR2018/09771T patent/TR201809771T4/tr unknown
- 2009-09-10 EA EA201170434A patent/EA020580B1/ru active Protection Beyond IP Right Term
- 2009-09-10 WO PCT/US2009/005082 patent/WO2010030359A2/en active Application Filing
- 2009-09-10 AU AU2009292182A patent/AU2009292182B2/en active Active
- 2009-09-10 EP EP12161047.1A patent/EP2468287B1/en active Active
- 2009-09-10 SI SI200930895T patent/SI2340029T1/sl unknown
- 2009-09-10 JP JP2009208935A patent/JP5259537B2/ja active Active
- 2009-09-10 PL PL12161047T patent/PL2468287T3/pl unknown
- 2009-09-10 SI SI200930952T patent/SI2468286T1/sl unknown
- 2009-09-10 EP EP14181565.4A patent/EP2805726B1/en active Active
- 2009-09-10 DK DK12161047.1T patent/DK2468287T3/da active
- 2009-09-10 PL PL09813360T patent/PL2340029T3/pl unknown
- 2009-09-10 DK DK14181565.4T patent/DK2805726T3/en active
- 2009-09-10 MX MX2011002486A patent/MX2011002486A/es active IP Right Grant
- 2009-09-10 ES ES14181565.4T patent/ES2677644T3/es active Active
- 2009-09-10 MY MYPI2011001033A patent/MY159820A/en unknown
- 2009-09-10 DK DK09813360.6T patent/DK2340029T3/da active
- 2009-09-10 NZ NZ592170A patent/NZ592170A/xx unknown
- 2009-09-10 PT PT121608491T patent/PT2468286E/pt unknown
- 2009-09-10 ES ES12160849.1T patent/ES2475815T3/es active Active
- 2009-09-10 ES ES12161047.1T patent/ES2475163T3/es active Active
- 2009-09-10 EP EP12160779.0A patent/EP2468285B1/en active Active
- 2009-09-10 DK DK12160779.0T patent/DK2468285T3/en active
- 2009-09-10 BR BR122012005261A patent/BR122012005261A8/pt active Search and Examination
- 2009-09-10 TW TW102140577A patent/TWI510245B/zh not_active IP Right Cessation
- 2009-09-10 BR BRPI0918724A patent/BRPI0918724B8/pt active IP Right Grant
- 2009-09-10 CA CA2736895A patent/CA2736895C/en active Active
- 2009-09-10 PT PT141815654T patent/PT2805726T/pt unknown
- 2009-09-10 EP EP12160849.1A patent/EP2468286B1/en active Active
- 2009-09-10 EA EA201200390A patent/EA022891B1/ru not_active IP Right Cessation
- 2009-09-10 SG SG2012014080A patent/SG179414A1/en unknown
- 2009-09-10 PE PE2012000653A patent/PE20121312A1/es not_active Application Discontinuation
- 2009-09-10 SI SI200931090T patent/SI2468285T1/sl unknown
- 2009-09-10 PL PL12160779T patent/PL2468285T3/pl unknown
- 2009-09-10 LT LTEP14181565.4T patent/LT2805726T/lt unknown
- 2009-09-10 PL PL12160849T patent/PL2468286T3/pl unknown
- 2009-09-10 PT PT98133606T patent/PT2340029E/pt unknown
- 2009-09-10 US US12/584,716 patent/US8420596B2/en active Active
- 2009-09-10 PE PE2013002396A patent/PE20140961A1/es not_active Application Discontinuation
- 2009-09-10 EP EP09813360.6A patent/EP2340029B1/en active Active
- 2009-09-10 PA PA20098842201A patent/PA8842201A1/es unknown
- 2009-09-10 HU HUE14181565A patent/HUE039478T2/hu unknown
- 2009-09-11 CN CN201410116146.2A patent/CN103896950A/zh active Pending
- 2009-09-11 CN CN2012100719006A patent/CN102641271B/zh not_active Expired - Fee Related
- 2009-09-11 CN CN200910175949.4A patent/CN101775017B/zh active Active
- 2009-09-11 KR KR1020090086079A patent/KR101379365B1/ko active Protection Beyond IP Right Term
-
2011
- 2011-02-28 ZA ZA2011/01558A patent/ZA201101558B/en unknown
- 2011-03-08 CO CO11028271A patent/CO6341565A2/es active IP Right Grant
- 2011-03-09 EC EC2011010879A patent/ECSP11010879A/es unknown
- 2011-03-10 CL CL2011000512A patent/CL2011000512A1/es unknown
- 2011-03-10 DO DO2011000077A patent/DOP2011000077A/es unknown
- 2011-03-28 GT GT201100056AK patent/GT201100056AA/es unknown
-
2012
- 2012-01-06 HK HK12100145.0A patent/HK1159515A1/xx unknown
- 2012-01-06 HK HK12111723.7A patent/HK1170937A1/zh not_active IP Right Cessation
- 2012-01-06 HK HK12111721.9A patent/HK1170936A1/xx not_active IP Right Cessation
- 2012-01-06 HK HK12111722.8A patent/HK1171184A1/xx not_active IP Right Cessation
- 2012-02-08 ZA ZA2012/00950A patent/ZA201200950B/en unknown
- 2012-03-01 IL IL218441A patent/IL218441A/en active IP Right Grant
- 2012-03-02 JP JP2012046166A patent/JP5534533B2/ja not_active Expired - Fee Related
- 2012-03-13 KR KR20120025541A patent/KR101487726B1/ko active IP Right Grant
- 2012-03-28 UY UY0001033981A patent/UY33981A/es not_active Application Discontinuation
- 2012-04-04 US US13/439,551 patent/US8642538B2/en active Active
- 2012-04-19 AR ARP120101342A patent/AR086181A2/es unknown
- 2012-06-04 EC ECSP12011947 patent/ECSP12011947A/es unknown
- 2012-06-07 CL CL2012001495A patent/CL2012001495A1/es unknown
-
2013
- 2013-04-25 JP JP2013092319A patent/JP5902123B2/ja not_active Expired - Fee Related
- 2013-04-25 JP JP2013092318A patent/JP5801342B2/ja not_active Expired - Fee Related
- 2013-12-10 GT GT201100056BA patent/GT201100056BA/es unknown
- 2013-12-11 AR ARP130104634A patent/AR093924A2/es unknown
-
2014
- 2014-01-08 UY UY0001035259A patent/UY35259A/es not_active Application Discontinuation
- 2014-01-31 US US14/170,199 patent/US9309279B2/en not_active Expired - Fee Related
- 2014-03-24 KR KR1020140034200A patent/KR20140056195A/ko not_active Application Discontinuation
- 2014-04-22 CR CR20140180A patent/CR20140180A/es unknown
- 2014-05-27 CY CY20141100378T patent/CY1115137T1/el unknown
- 2014-05-29 HR HRP20140493AT patent/HRP20140493T1/hr unknown
- 2014-05-29 HR HRP20140492AT patent/HRP20140492T1/hr unknown
- 2014-05-29 HR HRP20140494AT patent/HRP20140494T1/hr unknown
- 2014-06-27 CY CY20141100473T patent/CY1115202T1/el unknown
- 2014-07-11 CY CY20141100521T patent/CY1115379T1/el unknown
- 2014-10-02 IL IL234969A patent/IL234969A0/en unknown
- 2014-12-02 HR HRP20141169AT patent/HRP20141169T1/hr unknown
- 2014-12-31 CY CY20141101094T patent/CY1115844T1/el unknown
-
2015
- 2015-02-25 LU LU92667C patent/LU92667I2/xx unknown
- 2015-03-04 LT LTPA2015011C patent/LTC2340029I2/lt unknown
- 2015-03-26 CY CY2015014C patent/CY2015014I2/el unknown
- 2015-04-08 NL NL300730C patent/NL300730I2/nl unknown
- 2015-04-15 HU HUS1500020C patent/HUS1500020I1/hu unknown
- 2015-04-22 NO NO2015014C patent/NO2015014I1/no not_active IP Right Cessation
-
2018
- 2018-07-10 HR HRP20181075TT patent/HRP20181075T1/hr unknown
- 2018-07-16 CY CY181100737T patent/CY1120780T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0918724A8 (pt) | Composto inibidor de protease de serina para hepatite c macrocíclica | |
DOP2019000218A (es) | Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas | |
BR112012017382A2 (pt) | compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica | |
BR112012017402A2 (pt) | inibidores de vírus de flaviviridae | |
WO2011156337A3 (en) | Macrocyclic hepatitis c serine protease inhibitors | |
ECSP13012791A (es) | Inhibidores de serina proteasa de hepatitis c a base de macrocíclicos de fenantridina | |
BR112012018529A2 (pt) | inibidores do vírus de hepatite c, sua composição farmacêutica e seu uso, e método para inibição da replicação de um vírus contendo rna | |
CO7160104A2 (es) | Inhibidores de virus de hepatitis c | |
BR112014008495B8 (pt) | Composto inibidor da proteína quinase, composição farmacêutica compreendendo-o e uso do mesmo para a fabricação de um medicamento para o tratamento de câncer | |
CR11499A (es) | Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c | |
BR112014030649A2 (pt) | inibidores macrocíclicos da flaviviridae vírus | |
WO2012092409A3 (en) | Macrocyclic hepatitis c serine protease inhibitors | |
EA200970805A1 (ru) | Ингибиторы серинпротеаз для лечения hcv инфекций | |
BR112013023266A8 (pt) | Inibidores da girase tricíclicos | |
BR112013017977A2 (pt) | formas sólidas de inibidor de girase (r) 1-etil-3-[5-[2-{1-hidroxi-1-metil-etil}pirimidin-5-il]-7-(tetrai-drofuran-2-il)-1h-benzimidazol-2-il]ureia | |
BR112014012521A2 (pt) | novos derivados de pirrolidina como inibidores de catepsina | |
UA109532C2 (xx) | Макроциклічні інгібітори серинових протеаз гепатиту с | |
CR20110123A (es) | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE |
|
B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
B25C | Requirement related to requested transfer of rights |
Owner name: ENANTA PHARMACEUTICALS, INC. (US) , ABBOTT LABORAT |
|
B25A | Requested transfer of rights approved |
Owner name: ENANTA PHARMACEUTICALS, INC. (US) , ABBVIE INC (US |
|
B25A | Requested transfer of rights approved |
Owner name: ENANTA PHARMACEUTICALS, INC. (US) , ABBVIE BAHAMAS |
|
B25A | Requested transfer of rights approved |
Owner name: ENANTA PHARMACEUTICALS, INC. (US) , ABBVIE IRELAND |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |